The roles and limitations of bevacizumab in the treatment of ovarian cancer

Bevacizumab, an anti-VEGF antibody, targets mainly tumor blood vessels and exerts a cytostatic antitumor effect. In primary ovarian cancer, bevacizumab is used for 15 months, but its effect on progression-free survival disappears after 2 years and does not prolong overall survival. And in the treatm...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of clinical oncology Vol. 27; no. 7; pp. 1120 - 1126
Main Authors Nakai, Hidekatsu, Matsumura, Noriomi
Format Journal Article
LanguageEnglish
Published Singapore Springer Nature Singapore 01.07.2022
Springer Nature B.V
Subjects
Angiogenesis
Antitumor activity
Bevacizumab
Blood vessels
Cancer Research
Cancer therapies
Chemotherapy
Gynecology
Medicine
Medicine & Public Health
Obstetrics
Oncology
Ovarian cancer
Poly(ADP-ribose)
Poly(ADP-ribose) polymerase
Response rates
Review Article
Surgical Oncology
Survival
Tumors
Vascular endothelial growth factor
PARP inhibitor
Ovarian cancer
Bevacizumab
Online AccessGet full text

Cover

More Information
Summary:Bevacizumab, an anti-VEGF antibody, targets mainly tumor blood vessels and exerts a cytostatic antitumor effect. In primary ovarian cancer, bevacizumab is used for 15 months, but its effect on progression-free survival disappears after 2 years and does not prolong overall survival. And in the treatment of primary ovarian cancer, there is no evidence that bevacizumab increases the intratumor concentration of chemotherapy and enhances response rates. On the other hand, bevacizumab is not affected by resistance mechanisms to chemotherapeutic agents or poly(ADP-ribose) polymerase (PARP) inhibitors. In the era of using PARP inhibitors for primary ovarian cancer, bevacizumab will become a molecularly targeted drug that will play a central role in chemo-refractory and recurrent ovarian cancer.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1341-9625
1437-7772
DOI:10.1007/s10147-022-02169-x